The Efficacy and Safety of using Nebulized Antibiotics in Treatment of Ventilator-Associated Pneumonia
O.S.Arafa1, T.S.Essawy2 , B.M.Aglan3 and E.A.Attaya4"
Development of ventilator- associated pneumonia [VAP] is associated with high morbidity and mortality rates. VAP mortality ranges between 5.8% and 27% . Routine administration of intravenous antibiotics does not reach a bactericidal concentration in lung tissues. intravenous antibiotics are mainly detected in respiratory segments of lungs, but not in sputum .This study was conducted on 60 patients who were admitted to critical care department at Benha University Hospital and diagnosed with Ventilator Associated Pneumonia [VAP]. patients were divided into two groups: Group A included 30 patients have received only systemic antibiotics and Group B included 30 patients have received systemic and nebulized antibiotics. In this study the clearance of organism, resistance, superinfection and combined [resistance and super infection] were significantly different in group A vs.B .There was significant decrease regarding creatinine level in group B vs. A .There were significant reduction in duration of MV and length of ICU stay in group B vs. A.Nebulized Amikacin plus ceftazidime are effective in the treatment of VAP.
Nebulized Antibiotics, Ventilator-Associated Pneumonia